Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women

Therapeutic Drug Monitoring

Volumn 33, Issue 6, 2011, Pages 772-777

  Martinez Rebollar, Maria ^a   Lonca, Montserrat ^a   Perez, Iñaki ^b   Soy, Dolors ^b   Brunet, Mercè ^c   Martin, Rosa ^c   Coll, Oriol ^a   Hernandez, Sandra ^a   Laguno, Montserrat ^a   Milinkovic, Ana ^a   Larrousse, Maria ^a   Calvo, Marta ^a   Blanco, Jose L ^a   Martínez, Esteban ^a   Gatell, Jose M ^a   Mallolas, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Department of Biostatistics ^*  (Spain)

^c CDB   (Spain)

Author keywords

Antiretroviral therapy pharmacokinetics; Pregnancy; Saquinavir; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; ATAZANAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG FATALITY; DRUG HALF LIFE; DRUG SUBSTITUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; TABLET FORMULATION; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; COHORT STUDIES; FEMALE; HALF-LIFE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; OVERWEIGHT; PILOT PROJECTS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR;

EID: 84863414115     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318236376d     Document Type: Article

References (34)

1. Department for Health and Human Services (US), Public Health Service Task Force. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2010. Available at: http://www.aidsinfo.nih.gov/Content-Files/PerinatalGL.pdf. Accessed May 24, 2010.
2. Penzak SR, Acosta EP, Turner M, et al. Analysis of generic nevirapine products in developing countries. JAMA. 2003;289:2648-2649. (Pubitemid 37430134)
3. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825-829. (Pubitemid 40349795)
4. von Hentig N, Carlebach A, Gute P, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol. 2006;62:552-559. (Pubitemid 44571576)
5. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178:368-374. (Pubitemid 28347918)
6. Mirochnick M, Siminski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J. 2001;20:803-805. (Pubitemid 32758026)
7. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300. (Pubitemid 34118582)
8. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071-1087. (Pubitemid 40013177)
9. Roustit M, Jlaiel M, Leclercq P, et al. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol. 2008;66:179-195.
10. van der Lugt J, Colbers A, Burger D. Clinical pharmacology of HIV protease inhibitors in pregnancy. Curr Opin HIV AIDS. 2008;3:620-626.
11. Zhang H, Wu X, Wang H, et al. Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course. Mol Pharmacol. 2008;74:714-723.
12. Mathias AA, Maggio-Price L, Lai Y, et al. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2006;316:1202-1209. (Pubitemid 43345295)
13. Eley T, Vandeloise E, Chil M, et al. Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300mg once daily/ritonavir 100mg once daily+ZDV/3TC during the third trimester in HIV+ women. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
14. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS. 2007;21:1053-1054. (Pubitemid 46684341)
15. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS. 2007;21:643-645.
16. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931-1939. (Pubitemid 44427610)
17. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62:309-315. (Pubitemid 44215531)
18. ® product information [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2007.
19. la Porte CJ. Saquinavir, the pioneer antiretroviral protease inhibitor. Expert Opin Drug Metab Toxicol. 2009;5:1313-1322.
20. Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48:430-436. (Pubitemid 38141698)
21. Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000;30(suppl 2): S151-S159.
22. Acosta EP, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2:460-465. (Pubitemid 33138710)
23. Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit. 2007;29:171-176. (Pubitemid 46716182)
24. Lopez-Cortes LF, Ruiz-Valderas R, Pascual R, et al. Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin Trials. 2003;4:227-229. (Pubitemid 36748626)
25. Lonca M, Martínez-Rebollar M, Perez I, et al. Saquinavir 500mg formulation+ritonavir (1000/100mg bid) in HIV+ pregnant women: final results of a pilot pharmacokinetic study. Presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy; April 15-17, 2009; Amsterdam, the Netherlands.
26. van der Lugt J, Colbers A, Molto J, et al. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther. 2009;14:443-450.
27. van der Lugt J, Molto J, Hawkins D, et al. The influence of pregnancy on the pharmacokinetics of saquinavir boosted by low-dose ritonavir (1000/100mg BID). Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA.
28. von Hentig N, Nisius G, Lennemann T, et al. Pharmacokinetics, safety and efficacy of saquinavir/ritonavir 1, 000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther. 2008;13:1039-1046.
29. Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20:1401-1406. (Pubitemid 43948246)
30. National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS (DAIDS). Division of AIDS table for grading severity of adult adverse experiences. 1992. Available at: http://rsc.techres.com/Document/ safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-AEs-v01a.pdf. Accessed October 21, 2011.
31. Ghosn J, De Montgolfier I, Cornelie C, et al. Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy. Antimicrob Agents Chemother. 2008;52:1542-1544. (Pubitemid 351522030)
32. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51:783-786. (Pubitemid 46185308)
33. Hirt D, Urien S, Jullien V, et al. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. Br J Clin Pharmacol. 2007;64:634-644. (Pubitemid 47568807)
34. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 2007;21:2409-2415. (Pubitemid 350145172)